Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | CNR1 | P21554 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285784 | 0.85 | ALDH1A1 (0.76) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6519601 | 0.84 | ALDH1A1 (0.72) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6955039 | 0.84 | ALDH1A1 (0.68) | KMT2AALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL2636523 | 0.84 | MAPT (0.70) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6209685 | 0.84 | ALDH1A1 (0.70) | MEN1KMT2AALDH1A1LMNACNR1 | |
| SCHEMBL5244762 | 0.82 | MAPT (0.76) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3712663 | 0.82 | MAPT (0.76) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5246057 | 0.82 | MAPT (0.76) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL23498074 | 0.82 | ALDH1A1 (0.68) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5249802 | 0.82 | LMNA (0.71) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115003380-B | Compounds and their use for the treatment of alpha 1-antitrypsin deficiency | 森特萨制药(英国)有限公司 | 2024-04-02 | — | — | CN | claimed |
| EP-4072671-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-10-19 | — | — | EP | claimed |
| CN-115003380-A | Compounds and their use for the treatment of alpha 1-antitrypsin deficiency | Z因子有限公司 | 2022-09-02 | — | — | CN | claimed |
| WO-2021116703-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2021-06-17 | — | — | WO | claimed |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | claimed |
| EP-1758884-A2 | N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | claimed |
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | claimed |
| WO-2005113542-A2 | N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | WO | claimed |
| US-12611402-B2 | Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2026-04-28 | — | — | US | disclosed |
| EP-4072671-B1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | CENTESSA PHARMACEUTICALS UK LTD (GB) | 2025-09-17 | — | — | EP | disclosed |
| US-20240197707-A1 | Compositions and their Use for the Treatment of A1-Antitrypsin Deficiency | OXFORD FINANCE LLC | 2024-06-20 | — | — | US | disclosed |
| EP-4355328-A1 | COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF alpha1-ANTITRYPSIN DEFICIENCY | Centessa Pharmaceuticals (UK) Limited (GB) | 2024-04-24 | — | — | EP | disclosed |
| CN-115003380-B | Compounds and their use for the treatment of alpha 1-antitrypsin deficiency | 森特萨制药(英国)有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117794538-A | For the treatment of alpha 1 Composition for anti-trypsin deficiency and use thereof | 森特萨制药(英国)有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2021116703-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2021-06-17 | — | — | WO | disclosed |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | disclosed |
| US-7384970-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-06-10 | — | — | US | disclosed |
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| US-20040248887-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-12-09 | — | — | US | disclosed |
| WO-2004084843-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611402-B2 | Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency | SERPINA2, SERPINB1, SERPINE1 | MEN1 3098/4885KMT2A 4209/4885ALDH1A1 235/4885 |
| US-20040248887-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | MEN1 3815/4885KMT2A 4282/4885ALDH1A1 3512/4885 |
| US-20240197707-A1 | Compositions and their Use for the Treatment of A1-Antitrypsin Deficiency | SERPINA2, SERPINB1, SERPINC1 | MEN1 1667/4885KMT2A 3715/4885ALDH1A1 219/4885 |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | MEN1 3815/4885KMT2A 4282/4885ALDH1A1 3512/4885 |
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | BACE1, BACE2, APH1B | MEN1 2423/4885KMT2A 3354/4885ALDH1A1 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.